Hypoglycemic and hypolipidemic activity of methanolic leaf extract of Morinda lucida on alloxan induced diabetic rats
Healthy male wistar rats(30) of average weight of 150 – 190gm were randomly distributed into 5 gr. oups of six each. Group 1, normal control; each given only 0.2ml distilled water throughout the period of study; group 2 diabetic control, induced 150mg/kg b.w., i.p., administration of alloxan monohydrate and thereafter given 0.2ml distilled water throughout the period of study; group 3 and 4 diabetic (i.p., 150mg/kg b.w. alloxan), rats were orally administered methanolic leaf extract of Morinda lucida at 100mg/kg and 200mg/kg respectively for 15 days. Group 5 diabetic rat (i.p., 150mg/kg b.w. alloxan) were treated with 84mg/kg /b.w. of chlorpropamide once daily for 15 days. Serum glucose levels were found to decrease significantly (p<0.05) both in groups 3 and 4 compared to the control groups. Hypolipidemic status was found to improved significantly (p<0.05) by decreasing the levels of serum total cholesterol (TC), triglycerides (TGs) and low density hypoprotein (LDL) in both the treated groups compared to the control groups. These reductions were dose dependant and compared well with the values obtained in the standard drug control group. Thus, results of the study indicate that Morinda lucida methanolic leaf extract can be potentially used for diabetics to control glucose and lipid levels.
Keywords: Morinda lucida, Diabetes mellitus, hypoglycemic effect, hypolipidemic effect, chlorpropamide, alloxan monohydrate